XML 48 R35.htm IDEA: XBRL DOCUMENT
v3.20.2

SEGMENT AND GEOGRAPHIC INFORMATION (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2020
Segment Reporting [Abstract] |
Schedule of Net Sales and Profit by Segments | Total revenue by major geographic area consisted of the following:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
| (In thousands) |  | (In thousands)
United States | $ | 181,850 |  |  | $ | 273,390 |  |  | $ | 428,702 |  |  | $ | 530,116 |
Europe | 32,026 |  |  | 50,871 |  |  | 77,922 |  |  | 99,511 |
Asia Pacific | 33,501 |  |  | 37,031 |  |  | 73,461 |  |  | 72,731 |
Rest of World | 11,288 |  |  | 22,353 |  |  | 32,904 |  |  | 40,977 |
Total Revenues | $ | 258,665 |  |  | $ | 383,645 |  |  | $ | 612,989 |  |  | $ | 743,335 |
Net sales and profit by each reportable segment for the three and six months ended June 30, 2020 and 2019 are as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
| (In thousands) |  | (In thousands)
Segment Net Sales |  |  |  |  |  |  |
Codman Specialty Surgical | $ | 169,778 |  |  | $ | 249,258 |  |  | $ | 401,218 |  |  | $ | 483,826 |
Orthopedics and Tissue Technologies | 88,887 |  |  | 134,387 |  |  | 211,771 |  |  | 259,509 |
Total revenues | $ | 258,665 |  |  | $ | 383,645 |  |  | $ | 612,989 |  |  | $ | 743,335 |
Segment Profit |  |  |  |  |  |  |
Codman Specialty Surgical | $ | 65,256 |  |  | $ | 99,241 |  |  | $ | 152,491 |  |  | $ | 190,622 |
Orthopedics and Tissue Technologies | 28,688 |  |  | 41,787 |  |  | 59,958 |  |  | 82,282 |
Segment profit | 93,944 |  |  | 141,028 |  |  | 212,449 |  |  | $ | 272,904 |
Amortization | (8,073 | ) |  | (11,004) |  |  | $ | (15,050 | ) |  | (16,284) |
Corporate and other | (71,791 | ) |  | (84,065 | ) |  | (156,216 | ) |  | (178,353 | )
Operating income | $ | 14,080 |  |  | $ | 45,959 |  |  | $ | 41,183 |  |  | $ | 78,267 |
Schedule of Geographic Revenue by Area | Total revenue by major geographic area consisted of the following:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
| (In thousands) |  | (In thousands)
United States | $ | 181,850 |  |  | $ | 273,390 |  |  | $ | 428,702 |  |  | $ | 530,116 |
Europe | 32,026 |  |  | 50,871 |  |  | 77,922 |  |  | 99,511 |
Asia Pacific | 33,501 |  |  | 37,031 |  |  | 73,461 |  |  | 72,731 |
Rest of World | 11,288 |  |  | 22,353 |  |  | 32,904 |  |  | 40,977 |
Total Revenues | $ | 258,665 |  |  | $ | 383,645 |  |  | $ | 612,989 |  |  | $ | 743,335 |
Net sales and profit by each reportable segment for the three and six months ended June 30, 2020 and 2019 are as follows:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
| (In thousands) |  | (In thousands)
Segment Net Sales |  |  |  |  |  |  |
Codman Specialty Surgical | $ | 169,778 |  |  | $ | 249,258 |  |  | $ | 401,218 |  |  | $ | 483,826 |
Orthopedics and Tissue Technologies | 88,887 |  |  | 134,387 |  |  | 211,771 |  |  | 259,509 |
Total revenues | $ | 258,665 |  |  | $ | 383,645 |  |  | $ | 612,989 |  |  | $ | 743,335 |
Segment Profit |  |  |  |  |  |  |
Codman Specialty Surgical | $ | 65,256 |  |  | $ | 99,241 |  |  | $ | 152,491 |  |  | $ | 190,622 |
Orthopedics and Tissue Technologies | 28,688 |  |  | 41,787 |  |  | 59,958 |  |  | 82,282 |
Segment profit | 93,944 |  |  | 141,028 |  |  | 212,449 |  |  | $ | 272,904 |
Amortization | (8,073 | ) |  | (11,004) |  |  | $ | (15,050 | ) |  | (16,284) |
Corporate and other | (71,791 | ) |  | (84,065 | ) |  | (156,216 | ) |  | (178,353 | )
Operating income | $ | 14,080 |  |  | $ | 45,959 |  |  | $ | 41,183 |  |  | $ | 78,267 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration